Prader-Willi syndrome

Portnoy Law Firm launches class action lawsuit against $SLNO alleging concealment of safety issues in lead drug DCCR, following 27% stock plunge.

Securities class action filed against $SLNO over alleged misstatements about Prader-Willi drug safety risks. Lead plaintiff deadline set for May 5, 2026.

Investors in $SLNO have until May 5, 2026 to join securities lawsuit alleging undisclosed safety issues with DCCR drug candidate.

Soleno Therapeutics faces class action lawsuit alleging false safety disclosures about DCCR drug candidate for Prader-Willi syndrome.

Soleno Therapeutics faces class action lawsuit over safety concerns and inflated metrics for flagship drug VYKAT™ XR. Stock plunged 27% following August short report and November earnings disappointment.

Hagens Berman files securities class action against $SLNO alleging concealed safety risks and inflated metrics for hyperphagia drug VYKAT XR. Stock crashed 27% following August activist report and November earnings miss.

Soleno Therapeutics faces securities litigation alleging undisclosed DCCR safety risks during March-November 2025. Lead plaintiff deadline: May 5, 2026.

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

Rosen Law Firm alerts $SLNO investors of May 5, 2026 deadline in securities class action alleging false statements about DCCR drug candidate safety risks.

Portnoy Law Firm launches class action against $SLNO for allegedly concealing safety issues with lead drug DCCR, citing 27% stock plunge following patient death disclosure.

Aardvark Therapeutics ($AARD) plummeted 56% after pausing Phase 3 HERO trial for ARD-101 due to cardiac safety concerns, contradicting prior safety assurances.

Class action filed against $SLNO for allegedly failing to disclose safety concerns about DCCR drug. Stock fell sharply after August 2025 short report and September patient death disclosure.

Class action lawsuit filed against $SLNO for allegedly concealing safety concerns and patient death related to experimental drug DCCR, causing significant shareholder losses.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors have until May 5, 2026 deadline to join lawsuit.

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in all-cash deal, paying $53/share—a 34% premium driven by Soleno's FDA-approved Vykat XR for Prader-Willi Syndrome.

Neurocrine acquires Soleno for $2.9B to gain Vykat XR, a rare disease blockbuster generating $190M in 2025 revenue.

Rosen Law Firm alerts $SLNO investors about class action lawsuit alleging false statements regarding DCCR drug safety. Lead plaintiff deadline: May 5, 2026.

Class action lawsuit filed against $SLNO alleging fraud over PWS drug DCCR. Safety concerns, patient death, and commercial disruption emerged in 2025.

Securities class action filed against $SLNO over alleged false statements regarding safety risks in Phase 3 trial for Prader-Willi syndrome treatment. Lead plaintiff deadline: May 5, 2026.

Portnoy Law Firm sues Soleno Therapeutics for allegedly concealing DCCR safety risks in Phase 3 trials, citing 27% stock drop on November 4, 2025.